| 000 | 01187 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250517034830.0 | ||
| 264 | 0 | _c20160824 | |
| 008 | 201608s 0 0 eng d | ||
| 022 | _a1029-2403 | ||
| 024 | 7 |
_a10.3109/10428194.2015.1058937 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan der Weyden, Carrie | |
| 245 | 0 | 0 |
_aHigh-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from "orphan drug" to a standard-of-care? _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _c2016 |
||
| 300 |
_a1-3 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCentral Nervous System Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma _xdrug therapy |
| 650 | 0 | 4 | _aNervous System |
| 650 | 0 | 4 | _aOrphan Drug Production |
| 650 | 0 | 4 |
_aThiotepa _xtherapeutic use |
| 650 | 0 | 4 | _aTransplantation Conditioning |
| 700 | 1 | _aPrince, H Miles | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 57 _gno. 1 _gp. 1-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/10428194.2015.1058937 _zAvailable from publisher's website |
| 999 |
_c24967037 _d24967037 |
||